Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Dec 20;8(1):2045893217752329. doi: 10.1177/2045893217752329

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Fig. 1. — Impact of pathology on nanocarrier delivery to the inflamed lung. The left panel depicts mechanisms controlling sub-tissue delivery of PECAM-targeted (hypoxic vasoconstriction) and IgG-coated (capillary leak) nanocarriers in the unilateral ARDS mouse model. The top right depicts the localized injury induced in this model and the bottom right shows a semi-physiologic pharmacokinetic model describing sub-tissue nanocarrier disposition in this animal model, which described disposition using a one-compartment model linked to a physiolgic lung model. Within the lung space, nanocarriers were allowed to discribute based on physiologically relevant values to the injury model.